In my role as Chief Financial Officer at NKT Photonics, I advanced a clear business strategy which delivered profitable business growth. I executed a turnaround, setting up ‘best in class’ finance and IT organizations, advanced implementation of a new global ERP system and drove a clear digitalization strategy providing easy access to critical business information. The turnaround took NKT Photonics from no transparency to advanced transparency. The digitalization spans from advanced customer and financial data to production data enabling significant yield improvements. Activities included strategic review of alternatives for NKT Photonics with the objectives of maximizing value creation and positioning NKT Photonics for longterm growth.NKT Photonics is the leading supplier of high performance fiber lasers, fiber optic sensing systems, and photonic crystal fibers. Our main markets are within imaging, sensing and material processing. Our products include ultrafast lasers, supercontinuum white light lasers, low noise fiber lasers, distributed temperature sensing systems and a wide range of specialty fibers. NKT Photonics has its headquarters in Denmark with sales and service worldwide.

Growth and profitability focus turning Xellia Pharmaceuticals to profit making from 2016. Significant improvement of business performance transparency leading to renewed business strategy, long term plans and focused initiatives. Setting up Profitability Board and achieving improved profitability on important products, setting up offshore center achieving high quality and lower cost, Net Working Capital focus achieving 20% improvement. 
Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing clinically effective anti-infective treatments against serious and often life-threatening infections.With over 100 years of pharmaceutical industry expertise, we are a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and finished dosage forms (FDF), and the world-leading supplier of Vancomycin and Colistimethate Sodium (CMS). Our range of anti-infective treatments combat, most types of bacterial and antibiotic-resistant infections and certain fungal diseases.Xellia is wholly owned by Novo Holdings A/S, the holding Company of the Novo Group. Xellia employs 1,500 people and has research and development, manufacturing and commercial sites in eight countries. In the period 2014-2017 we successfully grew revenue with more than 50% and delivered an EBITDA margin increase from 6% to 27%.

Full responsibility of Novozymes Group financials, including group reporting, tax, treasury, risk management, acquisition Due Diligence.Audit Committee work.Due Diligence in numerous acquisition candidates. Member of Novozymes Sustainability Board, Business Integrity Committee, Employer Board.Best in class closing of books and first company to public annual report on the OMX for a number of years.

Full responsibility of Novozymes Group financials, including group reporting, tax, treasury, business controlling, risk management, acquisition Due Diligence.Set-up of Audit Committee and Enterprise Risk Management system. Thorough knowledge of Audit Committee work.Negotiation of Novozymes acquisitions in India, Canada and China. Furthermore involved in numerous acquisition candidates. Member of Novozymes Sustainability Board, Business Integrity Committee, Employer Board and Property Board. Sponsor of project leading to Novozymes obtaining Dow Jones Sustainability Index sector leader rating as well as Gold level rating.Transfer of significant tasks to Finance Service Center in India.Best in class closing of books and first company to public annual report on the OMX for a number of years.Bilateral Advanced Pricing Agreements with China and other countries.

Board member of joint venture companies in Japan and China.Acquisition of Chinese company, SAP implementation, Sale of property in Japan, Transform Japanese pension scheme from defined benefit plan to defined contribution plan, Safeguarding the financials during very significant growth period in China,

Financial responsibility for entities in Latin and North America.Transform US pension scheme from defined benefit plan to defined contribution plan, Integration of acquired entities.

Set-up Novozymes Asia Pacific management report.Implement ISO quality system for Finance and IT in Novozymes affiliates in Asia Pacific.

Localization of Finance Manager Position in Novo Nordisk China. Implementation of ERP and Payroll system in Novo Nordisk China, including consolidation of branches. Set up of advanced management reporting for Novo Nordisk China. Training Finance Organisation in the use of an advanced Finance & Logistics System.Tax optimisation of the Novo Nordisk China Entities.